Techne Corporation  

(Public, NASDAQ:TECH)   Watch this stock  
Find more results for Howard Blood
85.67
-0.54 (-0.63%)
After Hours: 85.65 -0.02 (-0.02%)
Apr 23, 5:11PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 85.30 - 86.54
52 week 62.55 - 96.96
Open 86.07
Vol / Avg. 0.00/222,806.00
Mkt cap 3.16B
P/E 27.75
Div/yield 0.31/1.45
EPS 3.09
Shares 36.90M
Beta 0.59
Inst. own 93%
Apr 28, 2014
Q3 2014 Techne Corp Earnings Release - 9:30AM EDT - Add to calendar
Apr 28, 2014
Q3 2014 Techne Corp Earnings Conference Call - 8:30AM EDT - Add to calendar
Feb 12, 2014
Techne Corp at Leerink Swann Global Healthcare Conference
Feb 4, 2014
Q2 2014 Techne Corp Earnings Release
Feb 4, 2014
Q2 2014 Techne Corp Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 29.82% 36.24%
Operating margin 42.54% 51.02%
EBITD margin - 54.99%
Return on average assets 12.71% 15.03%
Return on average equity 13.62% 15.94%
Employees 789 -
CDP Score - -

Address

614 McKinley Place N.E.
MINNEAPOLIS, MN 55413-2610
United States - Map
+1-612-3798854 (Phone)
+1-612-3796580 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TECHNE Corporation is engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. These activities are conducted through its wholly owned subsidiaries, Research and Diagnostic Systems, Inc. (R&D Systems), Boston Biochem, Inc. (Boston Biochem), and BiosPacific, Inc. (BiosPacific). The Company operates in two segments: biotechnology and hematology. The Company's biotechnology reporting segment develops, manufactures and sells biotechnology research and diagnostic products world-wide. The Company's hematology reporting segment, which consists of R&D Systems' Hematology Division, develops and manufactures hematology controls and calibrators for sale worldwide. In July 2013, the Company announced that it has completed the acquisition of Bionostics Holdings Limited and its operating subsidiary Bionostics, Inc. (Bionostics).

Officers and directors

Robert V. Baumgartner CPA Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Charles R. Kummeth President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Roger C. Lucas Ph.D. Independent Vice Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
James T. Hippel Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
Kevin Reagan Senior Vice President - Biotech
Age: 61
Bio & Compensation  - Reuters
Marcel Veronneau Senior Vice President - Clinical Controls
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
J. Fernando Bazan Ph.D. Chief Technology Officer
Age: 53
Bio & Compensation  - Reuters
Howard V. O'Connell Lead Independent Director
Age: 83
Bio & Compensation  - Reuters
Charles A. Dinarello M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
John L. Higgins Independent Director
Age: 43
Bio & Compensation  - Reuters